AbbVie Tells Jury Studies Don't Tie AndroGel To Heart Attacks
AbbVie Inc. told an Illinois federal jury Thursday that there are no studies definitively showing a connection between heart attacks and its testosterone product AndroGel, detailing its defense in a lawsuit...To view the full article, register now.
Already a subscriber? Click here to view full article